Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 12 | 2020 | 1224 | 1.460 |
Why?
|
| Magnetic Resonance Imaging, Cine | 8 | 2017 | 99 | 1.160 |
Why?
|
| Heart Failure | 7 | 2018 | 728 | 1.140 |
Why?
|
| Myocardial Perfusion Imaging | 5 | 2015 | 24 | 1.130 |
Why?
|
| Ventricular Function, Left | 8 | 2020 | 264 | 1.000 |
Why?
|
| Stroke Volume | 8 | 2020 | 417 | 0.990 |
Why?
|
| Coronary Circulation | 5 | 2015 | 41 | 0.910 |
Why?
|
| Antineoplastic Agents | 7 | 2020 | 595 | 0.860 |
Why?
|
| Anthracyclines | 6 | 2020 | 52 | 0.730 |
Why?
|
| Dobutamine | 3 | 2018 | 54 | 0.680 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2020 | 168 | 0.640 |
Why?
|
| Myocardium | 4 | 2016 | 184 | 0.630 |
Why?
|
| Predictive Value of Tests | 12 | 2020 | 883 | 0.560 |
Why?
|
| Myocardial Ischemia | 2 | 2018 | 98 | 0.550 |
Why?
|
| Heart | 2 | 2018 | 177 | 0.530 |
Why?
|
| Vasodilator Agents | 3 | 2014 | 62 | 0.520 |
Why?
|
| Coronary Vessels | 2 | 2014 | 174 | 0.490 |
Why?
|
| Hemodynamics | 3 | 2017 | 164 | 0.460 |
Why?
|
| Cardiotonic Agents | 1 | 2015 | 41 | 0.440 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2014 | 3 | 0.440 |
Why?
|
| Echocardiography, Stress | 1 | 2015 | 23 | 0.440 |
Why?
|
| Myocardial Infarction | 4 | 2019 | 466 | 0.440 |
Why?
|
| Myocardial Contraction | 1 | 2015 | 59 | 0.440 |
Why?
|
| Cardiomegaly | 1 | 2014 | 29 | 0.430 |
Why?
|
| Prediabetic State | 1 | 2015 | 76 | 0.410 |
Why?
|
| Dipyridamole | 1 | 2013 | 3 | 0.410 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2019 | 69 | 0.410 |
Why?
|
| Purines | 1 | 2013 | 21 | 0.400 |
Why?
|
| Adenosine | 1 | 2013 | 68 | 0.390 |
Why?
|
| Pyrazoles | 1 | 2013 | 77 | 0.390 |
Why?
|
| Cardiovascular System | 1 | 2013 | 49 | 0.390 |
Why?
|
| Vasodilation | 1 | 2013 | 92 | 0.390 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 1158 | 0.380 |
Why?
|
| Risk Factors | 13 | 2020 | 3934 | 0.380 |
Why?
|
| Female | 26 | 2020 | 19947 | 0.370 |
Why?
|
| Heart Ventricles | 3 | 2018 | 146 | 0.350 |
Why?
|
| Humans | 30 | 2020 | 32284 | 0.330 |
Why?
|
| Lung | 1 | 2012 | 263 | 0.330 |
Why?
|
| Risk Assessment | 6 | 2019 | 1425 | 0.330 |
Why?
|
| Male | 22 | 2020 | 19443 | 0.320 |
Why?
|
| Heart Valve Diseases | 1 | 2009 | 28 | 0.300 |
Why?
|
| Contrast Media | 3 | 2015 | 136 | 0.300 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2009 | 26 | 0.300 |
Why?
|
| Middle Aged | 19 | 2020 | 11853 | 0.290 |
Why?
|
| Hospital Mortality | 2 | 2019 | 197 | 0.280 |
Why?
|
| Neoplasms | 4 | 2020 | 754 | 0.270 |
Why?
|
| Heart Diseases | 2 | 2020 | 114 | 0.270 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 762 | 0.270 |
Why?
|
| Ventricular Remodeling | 3 | 2019 | 63 | 0.270 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2019 | 122 | 0.250 |
Why?
|
| Aged | 15 | 2020 | 10265 | 0.250 |
Why?
|
| Coronary Angiography | 2 | 2019 | 159 | 0.230 |
Why?
|
| Anemia | 1 | 2005 | 50 | 0.230 |
Why?
|
| Age Factors | 4 | 2018 | 1179 | 0.230 |
Why?
|
| Time Factors | 10 | 2020 | 2205 | 0.220 |
Why?
|
| Electrocardiography | 2 | 2019 | 623 | 0.210 |
Why?
|
| Heart Valve Prosthesis | 2 | 2017 | 58 | 0.200 |
Why?
|
| Survivors | 2 | 2016 | 173 | 0.200 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 534 | 0.190 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 3902 | 0.180 |
Why?
|
| Prognosis | 5 | 2019 | 1534 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 245 | 0.160 |
Why?
|
| Coronary Artery Disease | 2 | 2015 | 427 | 0.160 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 757 | 0.160 |
Why?
|
| Edema, Cardiac | 2 | 2016 | 12 | 0.150 |
Why?
|
| Doxorubicin | 1 | 2019 | 76 | 0.150 |
Why?
|
| Hospitals, University | 1 | 2019 | 27 | 0.150 |
Why?
|
| Disease Management | 1 | 2019 | 129 | 0.140 |
Why?
|
| Tricuspid Valve | 1 | 2017 | 5 | 0.130 |
Why?
|
| North Carolina | 3 | 2019 | 1300 | 0.130 |
Why?
|
| Stents | 2 | 2010 | 159 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2018 | 85 | 0.130 |
Why?
|
| Foramen Ovale, Patent | 1 | 2017 | 8 | 0.130 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2017 | 46 | 0.130 |
Why?
|
| Cardiac Volume | 1 | 2017 | 13 | 0.130 |
Why?
|
| Thrombosis | 1 | 2017 | 78 | 0.130 |
Why?
|
| Bioprosthesis | 1 | 2017 | 60 | 0.130 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 60 | 0.130 |
Why?
|
| Chest Pain | 1 | 2019 | 205 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 853 | 0.120 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 67 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 444 | 0.110 |
Why?
|
| Gadolinium | 1 | 2015 | 18 | 0.110 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2015 | 19 | 0.110 |
Why?
|
| Simvastatin | 1 | 2014 | 26 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 9 | 0.110 |
Why?
|
| Heptanoic Acids | 1 | 2014 | 33 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2020 | 2316 | 0.110 |
Why?
|
| Oxygen Consumption | 1 | 2015 | 141 | 0.110 |
Why?
|
| Aorta, Thoracic | 1 | 2015 | 81 | 0.110 |
Why?
|
| Aortic Diseases | 1 | 2015 | 62 | 0.110 |
Why?
|
| Pyrroles | 1 | 2014 | 59 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 39 | 0.110 |
Why?
|
| Animals | 4 | 2020 | 8199 | 0.100 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 73 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2015 | 471 | 0.100 |
Why?
|
| Infusions, Parenteral | 1 | 2013 | 63 | 0.100 |
Why?
|
| Adult | 8 | 2020 | 9259 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2013 | 57 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2014 | 242 | 0.100 |
Why?
|
| Fibrosis | 3 | 2019 | 126 | 0.100 |
Why?
|
| Sex Factors | 1 | 2015 | 657 | 0.100 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 15 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 167 | 0.090 |
Why?
|
| Ethnic Groups | 1 | 2015 | 450 | 0.090 |
Why?
|
| Registries | 2 | 2019 | 294 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2015 | 484 | 0.090 |
Why?
|
| Heart Rate | 1 | 2013 | 362 | 0.090 |
Why?
|
| Exercise Test | 3 | 2019 | 217 | 0.080 |
Why?
|
| Young Adult | 2 | 2017 | 2649 | 0.080 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2010 | 14 | 0.080 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2010 | 34 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2010 | 79 | 0.080 |
Why?
|
| Obstetric Labor Complications | 1 | 2009 | 18 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2009 | 40 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 187 | 0.070 |
Why?
|
| Bacteremia | 1 | 2009 | 66 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2015 | 820 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3628 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2009 | 122 | 0.070 |
Why?
|
| Aging | 1 | 2014 | 942 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2240 | 0.070 |
Why?
|
| New York | 1 | 2007 | 20 | 0.070 |
Why?
|
| Creatinine | 1 | 2007 | 191 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 287 | 0.060 |
Why?
|
| Pregnancy | 1 | 2009 | 961 | 0.060 |
Why?
|
| Logistic Models | 1 | 2007 | 743 | 0.060 |
Why?
|
| Disease Progression | 2 | 2018 | 591 | 0.060 |
Why?
|
| Erythropoietin | 1 | 2005 | 31 | 0.060 |
Why?
|
| Survival Rate | 2 | 2019 | 893 | 0.050 |
Why?
|
| Cytokines | 1 | 2005 | 237 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2005 | 173 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 312 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 556 | 0.040 |
Why?
|
| Prevalence | 2 | 2015 | 955 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1479 | 0.040 |
Why?
|
| Incidence | 2 | 2015 | 1241 | 0.040 |
Why?
|
| Cell Size | 1 | 2019 | 40 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 63 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2019 | 90 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3416 | 0.040 |
Why?
|
| Troponin | 1 | 2019 | 101 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2018 | 92 | 0.030 |
Why?
|
| Septal Occluder Device | 1 | 2017 | 7 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2019 | 341 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 107 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 504 | 0.030 |
Why?
|
| United States | 2 | 2016 | 4072 | 0.030 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 167 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 98 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 32 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 1083 | 0.030 |
Why?
|
| Hospitalization | 1 | 2018 | 475 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 651 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2015 | 66 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 565 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 256 | 0.030 |
Why?
|
| Brachial Artery | 1 | 2014 | 72 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 245 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 324 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2012 | 27 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2014 | 208 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 757 | 0.020 |
Why?
|
| Pyridines | 1 | 2010 | 79 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 285 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 555 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 541 | 0.020 |
Why?
|